2024-04-012025-03-312025-03-31false01656254BLOODAXE BOOKS LIMITED2025-11-2758110falseiso4217:GBPxbrli:pure016562542024-03-31016562542025-03-31016562542024-04-012025-03-31016562542023-03-31016562542024-03-31016562542023-04-012024-03-3101656254bus:SmallEntities2024-04-012025-03-3101656254bus:AuditExempt-NoAccountantsReport2024-04-012025-03-3101656254bus:FullAccounts2024-04-012025-03-3101656254bus:CompanyLimitedByGuarantee2024-04-012025-03-3101656254core:WithinOneYear2025-03-3101656254core:AfterOneYear2025-03-3101656254core:WithinOneYear2024-03-3101656254core:AfterOneYear2024-03-3101656254core:ShareCapital2025-03-3101656254core:SharePremium2025-03-3101656254core:RevaluationReserve2025-03-3101656254core:OtherReservesSubtotal2025-03-3101656254core:RetainedEarningsAccumulatedLosses2025-03-3101656254core:ShareCapital2024-03-3101656254core:SharePremium2024-03-3101656254core:RevaluationReserve2024-03-3101656254core:OtherReservesSubtotal2024-03-3101656254core:RetainedEarningsAccumulatedLosses2024-03-3101656254core:LandBuildings2025-03-3101656254core:PlantMachinery2025-03-3101656254core:Vehicles2025-03-3101656254core:FurnitureFittings2025-03-3101656254core:OfficeEquipment2025-03-3101656254core:NetGoodwill2025-03-3101656254core:IntangibleAssetsOtherThanGoodwill2025-03-3101656254core:ListedExchangeTraded2025-03-3101656254core:UnlistedNon-exchangeTraded2025-03-3101656254core:LandBuildings2024-03-3101656254core:PlantMachinery2024-03-3101656254core:Vehicles2024-03-3101656254core:FurnitureFittings2024-03-3101656254core:OfficeEquipment2024-03-3101656254core:NetGoodwill2024-03-3101656254core:IntangibleAssetsOtherThanGoodwill2024-03-3101656254core:ListedExchangeTraded2024-03-3101656254core:UnlistedNon-exchangeTraded2024-03-3101656254core:LandBuildings2024-04-012025-03-3101656254core:PlantMachinery2024-04-012025-03-3101656254core:Vehicles2024-04-012025-03-3101656254core:FurnitureFittings2024-04-012025-03-3101656254core:OfficeEquipment2024-04-012025-03-3101656254core:NetGoodwill2024-04-012025-03-3101656254core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3101656254core:ListedExchangeTraded2024-04-012025-03-3101656254core:UnlistedNon-exchangeTraded2024-04-012025-03-3101656254core:MoreThanFiveYears2024-04-012025-03-3101656254core:Non-currentFinancialInstruments2025-03-3101656254core:Non-currentFinancialInstruments2024-03-3101656254dpl:CostSales2024-04-012025-03-3101656254dpl:DistributionCosts2024-04-012025-03-3101656254core:LandBuildings2024-04-012025-03-3101656254core:PlantMachinery2024-04-012025-03-3101656254core:Vehicles2024-04-012025-03-3101656254core:FurnitureFittings2024-04-012025-03-3101656254core:OfficeEquipment2024-04-012025-03-3101656254dpl:AdministrativeExpenses2024-04-012025-03-3101656254core:NetGoodwill2024-04-012025-03-3101656254core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3101656254dpl:GroupUndertakings2024-04-012025-03-3101656254dpl:ParticipatingInterests2024-04-012025-03-3101656254dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3101656254core:ListedExchangeTraded2024-04-012025-03-3101656254dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3101656254core:UnlistedNon-exchangeTraded2024-04-012025-03-3101656254dpl:CostSales2023-04-012024-03-3101656254dpl:DistributionCosts2023-04-012024-03-3101656254core:LandBuildings2023-04-012024-03-3101656254core:PlantMachinery2023-04-012024-03-3101656254core:Vehicles2023-04-012024-03-3101656254core:FurnitureFittings2023-04-012024-03-3101656254core:OfficeEquipment2023-04-012024-03-3101656254dpl:AdministrativeExpenses2023-04-012024-03-3101656254core:NetGoodwill2023-04-012024-03-3101656254core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3101656254dpl:GroupUndertakings2023-04-012024-03-3101656254dpl:ParticipatingInterests2023-04-012024-03-3101656254dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3101656254core:ListedExchangeTraded2023-04-012024-03-3101656254dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3101656254core:UnlistedNon-exchangeTraded2023-04-012024-03-3101656254core:NetGoodwill2025-03-3101656254core:IntangibleAssetsOtherThanGoodwill2025-03-3101656254core:LandBuildings2025-03-3101656254core:PlantMachinery2025-03-3101656254core:Vehicles2025-03-3101656254core:FurnitureFittings2025-03-3101656254core:OfficeEquipment2025-03-3101656254core:AfterOneYear2025-03-3101656254core:WithinOneYear2025-03-3101656254core:ListedExchangeTraded2025-03-3101656254core:UnlistedNon-exchangeTraded2025-03-3101656254core:ShareCapital2025-03-3101656254core:SharePremium2025-03-3101656254core:RevaluationReserve2025-03-3101656254core:OtherReservesSubtotal2025-03-3101656254core:RetainedEarningsAccumulatedLosses2025-03-3101656254core:NetGoodwill2024-03-3101656254core:IntangibleAssetsOtherThanGoodwill2024-03-3101656254core:LandBuildings2024-03-3101656254core:PlantMachinery2024-03-3101656254core:Vehicles2024-03-3101656254core:FurnitureFittings2024-03-3101656254core:OfficeEquipment2024-03-3101656254core:AfterOneYear2024-03-3101656254core:WithinOneYear2024-03-3101656254core:ListedExchangeTraded2024-03-3101656254core:UnlistedNon-exchangeTraded2024-03-3101656254core:ShareCapital2024-03-3101656254core:SharePremium2024-03-3101656254core:RevaluationReserve2024-03-3101656254core:OtherReservesSubtotal2024-03-3101656254core:RetainedEarningsAccumulatedLosses2024-03-3101656254core:NetGoodwill2023-03-3101656254core:IntangibleAssetsOtherThanGoodwill2023-03-3101656254core:LandBuildings2023-03-3101656254core:PlantMachinery2023-03-3101656254core:Vehicles2023-03-3101656254core:FurnitureFittings2023-03-3101656254core:OfficeEquipment2023-03-3101656254core:AfterOneYear2023-03-3101656254core:WithinOneYear2023-03-3101656254core:ListedExchangeTraded2023-03-3101656254core:UnlistedNon-exchangeTraded2023-03-3101656254core:ShareCapital2023-03-3101656254core:SharePremium2023-03-3101656254core:RevaluationReserve2023-03-3101656254core:OtherReservesSubtotal2023-03-3101656254core:RetainedEarningsAccumulatedLosses2023-03-3101656254core:AfterOneYear2024-04-012025-03-3101656254core:WithinOneYear2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3101656254core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3101656254core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3101656254core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3101656254core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3101656254core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3101656254bus:Director12024-04-012025-03-3101656254bus:Director22024-04-012025-03-3101656254bus:Director32024-04-012025-03-3101656254bus:Director42024-04-012025-03-3101656254bus:Director52024-04-012025-03-3101656254bus:Director62024-04-012025-03-3101656254bus:Director72024-04-012025-03-3101656254bus:Director82024-04-012025-03-3101656254bus:Director92024-04-012025-03-31

BLOODAXE BOOKS LIMITED

Registered Number
01656254
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

BLOODAXE BOOKS LIMITED
Company Information
for the year from 1 April 2024 to 31 March 2025

Directors

ANDERSON, Prof L R
ASTLEY, Dr N P
CHALLIS, Dr J D
DHARKER, Dr I A
HERBERT, Prof W N
JONES, Ms B M
MACGREGOR, Ms C J
MORRISON-BELL, Sir W H D
TEITLER, Dr N S H

Company Secretary

MORRISON-BELL, William Hollin Dayrell, Sir

Registered Address

Eastburn
South Park
Hexham
NE46 1BS

Registered Number

01656254 (England and Wales)
BLOODAXE BOOKS LIMITED
Statement of Financial Position
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets46,3707,163
6,3707,163
Current assets
Stocks534,83437,636
Debtors690,545112,507
Cash at bank and on hand203,931218,099
329,310368,242
Creditors amounts falling due within one year7(78,318)(103,641)
Net current assets (liabilities)250,992264,601
Total assets less current liabilities257,362271,764
Provisions for liabilities8(1,611)(1,791)
Net assets255,751269,973
Capital and reserves
Profit and loss account255,751269,973
Reserves255,751269,973
The financial statements were approved and authorised for issue by the Board of Directors on 27 November 2025, and are signed on its behalf by:
ASTLEY, Dr N P
Director
Registered Company No. 01656254
BLOODAXE BOOKS LIMITED
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by guarantee and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
The directors have concluded that it continues to be appropriate to present the accounts on a Going Concern basis.
Judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. These critical accounting judgements and estimations are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. In assessing the level of obsolete stock, the directors have considered both external and internal sources of information such as market conditions, consumer demands and the experience of book sales.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and/or the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer.
Interest income
Interest income is recognised using the effective interest rate method.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Defined contribution pension plan
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further obligation. Contributions to defined contribution plans are expensed in the period to which they relate. Amounts not paid are shown in other creditors in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to the Income Statement
Current taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. The assets residual values, useful lives and depreciation methods are reviewed and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are recognised in the Income Statement Depreciation is provided on all tangible fixed assets as follows: Office Equipment - 20% Website - 20%
Stocks and work in progress
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price).
Financial instruments
The company enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
Government grants or assistance
Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to the Income Statement at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income. Grants of a revenue nature are recognised in the Income Statement in the same period as the related expenditure.
2.Average number of employees

20252024
Average number of employees during the year77
3.Further information regarding the company's income
Grant Funding Operating income in the year included Arts Council England grant funding amounting to £110,000 (2024: £110,000). Operating income also included grants toward production, rights, marketing or translation costs of the following specific books: English PEN translation grant (Holy Winter) £nil (2024: £1,556) English PEN translation grant (My Secret Life) £1,375 (2024: £nil) Harvard University production grant (Out of Sri Lanka) £nil (2024: £4,100) Newcastle University marketing grant (James Berry Poetry Prize) £nil (2024: £1,436) Newcastle University production grant (Hot Sauce: James Berry Poetry Prize) £nil (2024: £1,000) Newcastle University production grant (The Wrong Person to Ask: James Berry Poetry Prize) £nil (2024: £1,000) Flanders Literature translation grant (Inside of the Stone) £2,535 (2024:£nil) Institutul Cultural Roman translation and production grant (Shadow of Words) £9,815 (2024:£nil) Australia Council travel grant (The Jaguar) £2,610 (2024:£nil) Arts Council England has agreed further revenue funding of £110,000 for the next 12 months.
4.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 April 2423,75523,755
Additions1,0201,020
Disposals(1,039)(1,039)
At 31 March 2523,73623,736
Depreciation and impairment
At 01 April 2416,59216,592
Charge for year1,4321,432
On disposals(658)(658)
At 31 March 2517,36617,366
Net book value
At 31 March 256,3706,370
At 31 March 247,1637,163
5.Stocks

2025

2024

££
Finished goods34,83437,636
Total34,83437,636
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables54,80672,673
Other debtors9,3223,105
Prepayments and accrued income26,41736,729
Total90,545112,507
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables25,74639,818
Taxation and social security-4,283
Other creditors43,94947,794
Accrued liabilities and deferred income8,62311,746
Total78,318103,641
8.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)1,6111,791
Total1,6111,791
9.Related party transactions
The company was under the control of the directors throughout the current and previous year. Other than directors' remuneration, royalties paid to N P Astley of £3,343 (2024: £3,055), royalties and rights fee paid to I Dharker of £5,405, royalties paid to WN Herbert of £220, royalties paid to N Teitler of £1,263 and the balance due to the directors in the Directors Loan Account of £1,048 (included within Note 7 - Other Creditors) there were no other transactions between the company and the directors. No other transactions with related parties were undertaken such as are required to be disclosed under the Financial Reporting Standard 102 Section 1A.
10.Further information regarding the company's financial position
Company limited by guarantee The company is limited by guarantee and every member undertakes to contribute such an amount not exceeding £1 as may be required in the event of the company being wound up while they are a member or within 1 year after they cease to be a member, for payment of the debts and liabilities of the company and for the cost of winding up. Reserves Reserves include funds amounting to £40,000 which have been designated towards the future appointment of an additional editor or manager.